Tukysa Evrópusambandið - íslenska - EMA (European Medicines Agency)

tukysa

seagen b.v. - tucatinib - breast neoplasms; neoplasm metastasis - Æxlishemjandi lyf - tukysa is indicated in combination with trastuzumab and capecitabine for the treatment of adult patients with her2‑positive locally advanced or metastatic breast cancer who have received at least 2 prior anti‑her2 treatment regimens.

Tepmetko Evrópusambandið - íslenska - EMA (European Medicines Agency)

tepmetko

merck europe b.v. - tepotinib hydrochloride monohydrate - krabbamein, lungnakrabbamein - Æxlishemjandi lyf - tepmetko as monotherapy is indicated for the treatment of adult patients with advanced non-small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.

Amlodipin Bluefish Tafla 10 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

amlodipin bluefish tafla 10 mg

bluefish pharmaceuticals ab - amlodipinum besýlat - tafla - 10 mg

Amlodipin Bluefish Tafla 5 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

amlodipin bluefish tafla 5 mg

bluefish pharmaceuticals ab - amlodipinum besýlat - tafla - 5 mg

Tibsovo Evrópusambandið - íslenska - EMA (European Medicines Agency)

tibsovo

les laboratoires servier - ivosidenib - leukemia, myeloid, acute; cholangiocarcinoma - Æxlishemjandi lyf - tibsovo in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) with an isocitrate dehydrogenase-1 (idh1) r132 mutation who are not eligible to receive standard induction chemotherapy (see section 5. tibsovo monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an idh1 r132 mutation who were previously treated by at least one prior line of systemic therapy.

Litfulo Evrópusambandið - íslenska - EMA (European Medicines Agency)

litfulo

pfizer europe ma eeig - ritlecitinib tosilate - alopecia areata - Ónæmisbælandi lyf - litfulo is indicated for the treatment of severe alopecia areata in adults and adolescents 12 years of age and older.